A phase 2 trial of pre-phase treatment before R-CHOP chemotherapy in elderly patients with newly diagnosed DLBCL
R-CHOP Chemotherapy Cataract treatment with anterior steroids Phenotypic effects Evaluate the felony associated with the procedure for the primary purpose. This study evaluated efficacy, treatment outcome and safety for all patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
37
Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
Kosin University Gospel Hospital
Busan, Sue-gu, South Korea
(treatment-related mortality rate; TRM)
treatment-related mortality rate
Time frame: an average of 1 year
IMWG fragility score before and after pre-phase treatment
International Myeloma Working Group,( IMWG)
Time frame: an average of 1 year
TRM and RR according to IMWG fragility score
International Myeloma Working Group,( IMWG)
Time frame: an average of 1 year
response rate; RR
response rate
Time frame: an average of 1 year
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
safety
Time frame: an average of 1 year
Incidence of neutropenic fever
Incidence of neutropenic fever
Time frame: an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.